Early Stage Partners, LP — 2020 Investments

1 investments dated 2020 · listed companies and verified rows first · show all

SeaStar Medicalseastarmedical.com in 𝕏NASDAQ: ICUJul 2020

SeaStar Medical develops the Selective Cytopheretic Device (SCD), a therapy that targets highly activated neutrophils and monocytes to neutralize the hyperinflammatory immune response in critically ill ICU patients facing conditions such as infection, trauma, or surgery.

BiotechHealthtechMedical DevicesDenver, US

H David Humes(Director)Eric Schlorff(Executive Officer, Director)inPeter DeComo(Director)Mark Morsfield(Executive Officer)inR James Danehy(Executive Officer, Director)Jen Baird, NACD.DCin

Co-investorsAphelion Capital Capital Midwest Fund WMU Biosciences Research & Commercialization Center

Rows marked “SEC filing” are inferred from directors named on the company's SEC Form D — public regulatory data, not a portfolio list published by the firm.